상세 정보

underline
Metadata Downloads : dc(xml) or Excel
Cited 0 time in scopus ci

Title 

Therapeutic strategies for metabolic diseases: small-molecule diacylglycerol acyltrasferase (DGAT) inhibitors

 

대사질환 치료제로서의 DGAT 저해제 리뷰

Authors 

R NaikB W Obiang-ObounouM KimY ChoiHyun Sun LeeK Lee

Publisher 

Wiley-VCH Verlag

Issue Date 

2014

Citation 

ChemMedChem, vol. 9, no. 0, pp. 2410-2424

Keywords 

DGATdiacylglycerol acyltransferasemetabolic disorderssmall-molecule inhibitorstriacylglycerides

Abstract 

Metabolic diseases such as atherogenic dyslipidemia, hepatic steatosis, obesity, and type?II diabetes are emerging as major global health problems. Acyl-CoA:diacylglycerol acyltransferase (DGAT) is responsible for catalyzing the final reaction in the glycerol phosphate pathway of triglycerol synthesis. It has two isoforms, DGAT-1 and DGAT-2, which are widely expressed and present in white adipose tissue. DGAT-1 is most highly expressed in the small intestine, whereas DGAT-2 is primarily expressed in the liver. Therefore, the selective inhibition of DGAT-1 has become an attractive target with growing potential for the treatment of obesity and type?II diabetes. Furthermore, DGAT-2 has been suggested as a new target for the treatment of DGAT-2-related liver diseases including hepatic steatosis, hepatic injury, and fibrosis. In view the discovery of drugs that target DGAT, herein we attempt to provide insight into the scope and further reasons for optimization of DGAT inhibitors.

ISSN 

1860-7187

Link 

http://dx.doi.org/10.1002/cmdc.201402069

Appears in Collections

1. Journal Articles > Journal Articles

Registered Date

2019-05-02


There are no files associated with this item.
qrcode

FusionCharts.
DSpace Software Coptright(c) 2010 MIT and Hewleft-Packard  /  KRIBB-REPOSITORY ( Email:jakim@kribb.re.kr)